#VELA Vela Technologies – Investee Company #KING Igraine Plc Notice of AGM and Share Purchase October 13, 2022 – Posted in: Blog, Vela Technologies Plc (VELA)

SHARE PURCHASE Igraine Plc is pleased to announce that it has [today] purchased 21,475,000 ordinary shares of Oscillate plc, representing approximately 10.2% of Oscillate’s issued share capital, for a total consideration of £268,437. This diversifies the Igraine holding with the idea of obtaining pre-IPO positions in companies that have sufficient cash resources to undertake transactions. Simultaneously with the share purchase, it has been agreed that Stephen Winfield, Executive Director of the Company, will join…

Open Orphan (ORPH) – Early adopters signed for Genomic Health DataBANK November 25, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform. The platform is expected to be completed and rolled out in Q1 2020. The five companies signed up to the Genomic Health DataBANK platform will ensure the database is ‘fit-for-purpose’ from a pharmaceutical and data analysis perspective ahead of the first patient data upload. This builds…

Open Orphan (ORPH) Contract signed with Carna Bioscience November 18, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with Carna Bioscience (“Carna”) (www.carnabio.com) for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve months. Carna is a Japanese company specialising in kinase biology, developing innovative treatments against cancer and immune disorders. This contract sees Venn Life Sciences (“Venn”), part…

Open Orphan (ORPH) to attend Jefferies 2019 London Healthcare Conference November 15, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending the Jefferies 2019 London Healthcare Conference on 20th-21st November 2019 in London, UK. The conference will be attended by a range of international healthcare executives and institutional investors who will gather to address near and long-term investment opportunities and to discuss the mechanisms driving global healthcare. Open Orphan’s Chief Executive Officer, Cathal Friel, will be in attendance and will…

Tiziana Life Sci – Positive Phase 2a Clinical Data September 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma New York/London, 4 September 2019 – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced additional positive Phase 2a clinical data exhibiting impressive clinical activity of Milciclib monotherapy in…

Global Orphan Drugs Market Growth, Trends and Forecasts 2019-2024 – Business Wire August 19, 2019 – Posted in: Open Orphan (ORPH)

Article from BusinessWire.com The orphan drugs market is expected to register a CAGR of 11.5% over the forecast period Factors that are responsible for the growth of this market include market exclusivity for orphan drug developers, the rising prevalence of rare diseases, and favorable government policies. The market is expected to register an increased CAGR during the forecast period because the prevalence of rare diseases among the global population has been increasing in recent years.…

#VELA Vela Technologies – Investee Company #KING Igraine Plc Notice of AGM and Share Purchase October 13, 2022 – Posted in: Blog, Vela Technologies Plc (VELA)

Open Orphan (ORPH) – Early adopters signed for Genomic Health DataBANK November 25, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan (ORPH) Contract signed with Carna Bioscience November 18, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan (ORPH) to attend Jefferies 2019 London Healthcare Conference November 15, 2019 – Posted in: Open Orphan (ORPH)

Tiziana Life Sci – Positive Phase 2a Clinical Data September 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Global Orphan Drugs Market Growth, Trends and Forecasts 2019-2024 – Business Wire August 19, 2019 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL